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The purpose of the present study was to evaluate the changes in successive chest CT examinations in patients with
pulmonary tuberculosis who achieved culture conversion with linezolid treatment. We reviewed the follow-up CT
scans of 14 patients with pulmonary tuberculosis who had sputum-culture conversion after linezolid treatment.
This study evaluated cavity, centrilobular nodules, consolidation, bronchial wall thickening, calcified nodule or
consolidation, bronchiectasis, irregular lines, and lung destruction. The presence of pleural thickening, pleural effusion
and lymphadenopathy was recorded. Follow-up CT scans showed a partial decrease in the extent of centrilobular
nodules in all cases. Consolidation was partially cleared in 8 patients and newly developed consolidation was
observed in 2 patients. All of the cavities showed a decrease in size and thickness. But the cavities persisted after
linezolid treatment in 8 of 9 patients. Bronchial wall thickening was completely or partially cleared in 6 patients
and 5 patients, respectively. Newly developed irregular lines, lung destruction and pleural thickening were observed in
1, 1, and 3 patients, respectively. Successive chest CT examinations in patients with linezolid treatment may help in the
early assessment of linezolid treatment efficacy because of its rapid availability. Early assessment of linezolid treatment
efficacy will help to set up a treatment plan, such as duration of treatment or linezolid dosage. However, they may not
be useful for deciding pulmonary tuberculosis activity following linezolid treatment.
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Although the overall prevalence of drug-susceptible
tuberculosis has reduced, the worldwide incidences of
multidrug-resistant (MDR) tuberculosis and extensively
drug-resistant (XDR) tuberculosis during the past decade
threaten tuberculosis control since treatment is less
effective, more complex, and far more costly than that
for drug-susceptible disease (Frieden et al. 1993; Shah
et al. 2007; Raviglione 2007). Linezolid (Zyvox, Pfizer)
was approved in 2000 for drug-resistant, gram-positive
bacterial infections (Leach et al. 2011). Linezolid has
been shown to be effective in the treatment of MDR-
tuberculosis (TB) and XDR-TB (Anger et al. 2010; Singla
et al. 2012; Condos et al. 2008). However, several studies
have reported side effects and toxicities, primarily bone
marrow suppression and peripheral and optic neuropathy,
to be limiting factors in the use of linezolid (Di Paolo et al.* Correspondence: sanghyeon-kim@daum.net
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in any medium, provided the original work is p2010; Lee et al. 2003). Determination of disease activity
must be based on the results of sputum cultures. Although
performing sputum culture is much faster nowaday,
determination of drug resistance still takes several
weeks. In such situation, chest CT may help in the early
assessment of linezolid treatment efficacy because of its
rapid availability.
The purpose of the present study was to evaluate the
changes in successive chest CT examinations in patients
with pulmonary tuberculosis who achieved culture con-
version with linezolid treatment.Materials and methods
Patients and diagnoses
Masan National Hospital approved this study. The re-
quirement of informed consent was waived for this
retrospective study.
From September 2008 through March 2013, a com-
puter search was performed to identify all patients with
pulmonary tuberculosis who were treated with linezolid.
Fifty-three patients with pulmonary tuberculosis had beenOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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or more before linezolid treatment and received linezolid
without a change in their background treatment regimen.
Among these 53 patients, we enrolled 14 patients who
had sputum-culture conversion with linezolid treatment
and whose serial CT scan were available. We compared
two serial CT studies: the first CT scan before linezolid
treatment and the second CT study after sputum-culture
conversion with linezolid therapy. Conversion was defined
as negative sputum samples on solid medium for 3 con-
secutive weeks. The time between the negative sputum
and the second CT scan ranged from 28 days to 12
months (mean, 4.8 months ± 3.3). The interval between
the first and second CT scans ranged from 5 to 14 months
(mean, 7.2 months ± 2.6).
All 14 patients enrolled in this study were HIV-
seronegative as documented by negative results of a Western
blot or an enzyme-linked immunosorbent assay test.
Image acquisition and analysis
All CT examinations were performed using a 4-detector
row spiral CT scanner (Asteion; Toshiba Medical, Tokyo,
Japan). None of the patients were administered an
intravenous injection of contrast medium. Data were
reconstructed using a bone algorithm. Scanning was
performed at 120 kV with a 512 × 512 matrix. Data were
reconstructed using a 2.5-mm thickness for transaxial
images.
Chest CT scans were reviewed by two radiologists (SHK
and JYL) with 3 and 14 years’ experience who had no
knowledge of the patients’ clinical information. A final
decision regarding the findings was determined by con-
sensus. The assessed patterns of pulmonary parenchymal
abnormalities included the following: centrilobular nod-
ules (including a tree-in-bud pattern), cavity (site, number,
size of the largest cavity and thickness), consolidation,
bronchial wall thickening, calcified nodule or consolida-
tion, bronchiectasis, irregular lines, and lung destruction.
The descriptive terms used to interpret CT findings were
as follows (Hansell et al. 2008): (i) centrilobular nodule: a
nodule separated by several millimeters from the pleural
surfaces, fissures, and interlobular septa; (ii) tree-in-bud
pattern: centrilobular branching structures that resemble
a budding tree; (iii) cavity: a gas-filled space, seen as a
lucency or lowattenuation area, within pulmonary con-
solidation, a mass or nodule. Identification of bronchial
wall thickening is largely subjective. Because bronchial
wall thickening often is multifocal rather than diffuse
and uniform, we compared the bronchial wall thickness
of one lung region to another. The operational definition
of lung destruction was one lobe or a lung with paren-
chymal distortion, bronchiectasis, and a decreased vol-
ume below half that of a normal lung. The cavities in
areas of destroyed lung were not counted. In addition,the presence of mediastinal or hilar lymph node enlarge-
ment and pleural effusion or thickening was recorded.
Enlarged lymph nodes were defined as having a short-
axis diameter >1 cm on the CT scan. Each finding was
classified at the second evaluation as completely or partially
cleared, stable, increased, or newly developed.
Results
Patient demographics
Patients comprised of 10 males and 4 females (mean
age, 39 years; age range, 23–59 years). Three MDR TB
organism (defined as no resistance to isoniazid, rifampin,
ethambutol, and pyrazinamide) and 11 XDR TB organ-
isms were isolated. XDR TB is caused by a strain of
Mycobacterium tuberculosis that is resistant to any type
of fluoroquinolones and to at least one of the following
three injectable drugs: amikacin, capreomycin or kanamy-
cin in addition to isoniazid and rifampin and MDR TB is
caused by mycobacteria resistant to at least isoniazid
and rifampin (World Health Organization 2006).
Imaging findings
Initial CT appearances
The most common site for the cavity includes the upper
lobe in 13 patients and superior segment of the lower
lobe in 9 patients. The mean number of involved lobes
affected by parenchymal lesions was 4.8. In the order of
their frequency, centrilobular nodules (93%), irregular lines
(93%), pleural thickening (86%), bronchial wall thickening
(79%), consolidation (71%), cavity (64%), bronchiectasis
(64%) were observed. The average number of the cavity
was 2.9, and the average size of cavities was 37.7 mm.
The maximal thickness of the cavity wall was from 2 to
7 mm. The average thickness of the cavity wall was 3.8
mm. Lung destruction, calcified nodule or consolidation,
lymphadenopathy and pleural effusion were observed
occasionally (Table 1).
Follow-up CT appearances
Follow-up CT scans showed a partial decrease in the
extent of centrilobular nodules in all cases (Figure 1).
Consolidation was partially cleared in 8 patients and
newly developed consolidation was observed in 2 patients.
Majority of the cavities usually heal as linear or fibrotic
lesions or disappear completely after conventional treat-
ment. But, in our study, the cavities persisted after
linezolid treatment in 8 of 9 patients. The average
number of cavities was 1.35, and the average size of
the cavity was 27 mm. The maximal thickness of the
cavity wall was from 1 to 4.2 mm. The average thickness
of the cavity wall was 2.1 mm. Bronchial wall thickening
was completely or partially cleared in 6 patients and 5
patients, respectively (Figure 2). Newly developed irregular
lines, lung destruction and pleural thickening were
Table 1 Evolution of pleural and pulmonary lesions after linezolid treatment by CT in 14 patients with
pulmonary tuberculosis







Centrilobular nodules 13 (93) 0 13 (93) 0 0
Consolidation 10 (71) 0 8 (57) 0 2 (14)
Cavity 9 (64) 1 (7) 7 (50) 1 (7) 0
Bronchial wall thickening 11 (79) 6 (43) 5 (36) 0 0
Calcified nodule or consolidation 5 (36) 0 0 5 (36) 0
Bronchiectasis 9 (64) 0 0 9 (64) 0
Irregular lines 13 (93) 0 0 12 (86) 1 (7)
Lung destruction 6 (43) 0 0 5 (36) 1 (7)
Pleural thickening 12 (86) 0 0 9 (64) 3 (22)
Pleural effusion 1 (7) 1 (7) 0 0 0
Lymphadenopathy 2 (14) 0 0 2 (14) 0
The values in parentheses are percentages.
Kim et al. SpringerPlus 2013, 2:615 Page 3 of 5
http://www.springerplus.com/content/2/1/615observed in 1, 1, and 3 patients, respectively. Pleural
effusion was completely cleared and lymphadenopathy
was stable in all cases.
Discussion
Linezolid is a new antibiotic with activity against Myco-
bacterium tuberculosis and has been used to treat MDR
and XDR TB with clinical improvement. Linezolid’s safety
and tolerability are limited by the dose- and duration-
dependent occurrence of reversible myelosuppression
and peripheral and optic neuropathy (Bressler et al. 2004;
Rucker et al. 2006). Early assessment of linezolid treatment
efficacy is necessary. In addition to the diagnosis of TB,Figure 1 A, B, C, D Extensively drug-resistant tuberculosis in a 33-yea
centrilobular nodules (arrows) in the right upper lobe (A) and a cavity in th
shifting. C and D. After 8 months of linezolid treatment, CT scan shows par
(C) and the decrease of cavity size in the right lower lobe (D).CT is useful in determining disease activity (Jeong &
Lee 2008). In the series by Lee et al. (Lee et al. 1996),
80% of patients with active disease and 89% of those
with inactive disease were correctly differentiated on
high-resolution CT.
CT is more sensitive than chest radiography in the
detection and characterization of both subtle localized
or disseminated parenchymal disease (McGuinness et al.
1992; Kim et al. 1997). The most common CT findings of
active pulmonary TB are centrilobular small nodules,
branching linear and nodular opacities (tree-in-bud sign),
patchy or lobular areas of consolidation, and cavitation
(Lee et al. 1993). Lesions including areas of irregular lines,r-old man. A and B. Transaxial thin-section CT scan shows multiple
e right lower lobe (B). Also note destroyed left lung with mediastinal
tial improvement of pulmonary nodules in the right upper lobe
Figure 2 A, B, C Extensively drug-resistant tuberculosis in a 58-year-old man. He had been treated with antituberculosis drugs for 6 months
before linezolid treatment. A and B. Transaxial thin-section CT scan shows a cavity (arrow) and bronchial wall thickening in the right upper
lobe. Bronchial wall thickening and decreased volume in the right lobe are also noted. Calcified nodule ((B) mediastinal window, arrowhead)
and pleural thickening with extrapleural fat proliferation are also observed. C. After 6 months of linezolid treatment, CT scan shows a persistent cavity
with a decreased size and thin wall in the right upper lobe (arrow). Bronchial wall thickening improved.
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bundles, bronchiectasis, pericicatricial emphysema, or a
combination of the above were presumed to be inactive
(Lee & Im 1995). Lee et al. (Lee et al. 1996) showed that
calcified nodule or consolidation, irregular lines, parenchy-
mal bands, and pericicatricial emphysema were unique
findings that were observed only in patients with inactive
pulmonary tuberculosis. However, in our study, the initial
CT study showed these findings in most of the patients.
These findings can be explained based on the patients’ the
clinical history, namely, a chronic course of the disease.
All of the patients had been treated with antituberculosis
drugs for 6 months or more before enrollment in our study.
Radiological findings might show inadvertently progressive
features with an ongoing chronic TB infection.
The most important finding for making an accurate
diagnosis of active tuberculosis on CT is the endobronchial
spread of infection. The centrilobular small nodules and
tree-in-bud sign reflect the presence of endobronchial
spread (Leung 1999). With more extensive disease, co-
alescence of the centrilobular opacities occurs, resulting in
focal areas of bronchopneumonia. In our study, these
findings of infection, such as centrilobular nodules, con-
solidation and bronchial wall thickening were commonly
observed in the initial CT scan. Bronchial wall thickening
disappeared completely in 6 patients or partially in 5
patients. However, centrilobular nodules and consolidation
were not completely cleared, and they persisted in all
patients except for two patients in spite of negative
sputum following linezolid treatment. Two patients showednewly developed consolidation but one of the two patients
was available for further follow-up CT that did not show a
significant change.
Cavities are the radiologic hallmark of reactivation TB
(Miller & Miller 1993). Majority of the cavities usually
heal as linear or fibrotic lesions or disappear completely.
However, complete anatomical clearing of the cavities
after adequate therapy dose not always take place. Some
cavities persist even after antituberculous therapy. In 8
of 9 patients with cavities, the cavities became smooth
and smaller with linezolid treatment but they persisted.
Thus, CT findings of pulmonary TB such as persistent
centrilobular nodules, consolidation or cavities may cause
confusion regarding pulmonary tuberculosis activity after
linezolid treatment.
There are some reports about the difference in CT
findings between drug-sensitive TB and XDR/MDR TB.
Multiple cavities and findings of chronicity such as bron-
chiectasis and calcified granulomas are more common in
patients with MDR TB than drug-sensitive TB (Kim et al.
2004; Chung et al. 2006). CT findings of pulmonary XDR
TB are similar to those of non XDR MDR-TB (Lee et al.
2010; Cha et al. 2009). Similarly, there is no significant
difference in imaging findings between patients with
XDR TB and MDR TB in our study.
This study has some limitations. First, there might be
some selection bias in this study, because not all of the
patients with pulmonary tuberculosis underwent a CT
scan. Second, the population studied was small, and
hence, there were no controls.
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patients with linezolid treatment may help in the early
assessment of linezolid treatment efficacy because of its
rapid availability. Early assessment of linezolid treatment
efficacy will help to set up a treatment plan, such as
duration of treatment or linezolid dosage. However, they
may not be useful for deciding pulmonary tuberculosis
activity following linezolid treatment.
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